The drug has been previously approved in Europe for the treatment of cystic fibrosis patients ages 12 months and older.
The marketing clearance is subject to final approval by the European Commission.
Shares were little changed before midday.
Price: 177.27, Change: -0.45, Percent Change: -0.25
|US Bancorp Subsidiary to Acquire Sage Pay|
|Market Chatter: Ethiopian Airlines Yet to Decide Whe...|
|AstraZeneca Reports Positive Results From Studies of...|
|Market Chatter: FAA Mulls Amending Certification Pro...|
|Forex Update: GBP Rises by Nearly 0.5% Versus USD at...|